The association between EGFR mutation status and BM in NSCLC patients has previously been investigated, although no clear conclusions could be drawn from those investigations [10–14], with the molecular aspects of the pathway by which EGFR-mutated cancer cells metastasize remaining unclear to date. Here, EGFR is linked to cancer.